Treatment with PD-CLD-Fc also resulted in a statistically significant reduction in the severity of lung pathology as measured by a composite index of alveolitis, pneumocyte hyperplasia, vasculitis, interstitial hyperplasia, lesion extent, and bronchitis (Fig. 5D). The gene discussed is SLC26A3; the disease is hypersensitivity pneumonitis.